
AbbVie buys Apogee for $11B, boosting its drug pipeline and keeping 'Buy' rating intact.
AbbVie confirmed its $11 billion acquisition of Apogee Therapeutics, enhancing its drug pipeline in immunology, oncology, neuroscience, and aesthetics. The deal causes only modest near-term earnings dilution. AbbVie's Q2 results beat expectations, dr...



